Study of CAR-T cells for relapsed/refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests two new CAR-T cell therapies (LCAR-M61S and LCAR-M61D) for people whose multiple myeloma has come back or stopped responding to at least three prior treatments. The treatment uses your own immune cells that are modified to find and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already tried at least 3 different treatments for multiple myeloma, and your disease got worse during or after one of them.
- You are 18 years or older.
- You are in generally good health (able to care for yourself, up and about more than half the day).
- You have not had treatment that targets GPRC5D or CD19 proteins before.
- You do not have other serious medical conditions like active hepatitis B, hepatitis C, HIV, or heart/lung/kidney disease.
- You are not pregnant, breastfeeding, or planning to become pregnant in the next year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy called LCAR-M61SQ for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It aims to see if this therapy can help control the disease.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new CAR-T cell therapy called LCAR-F33S for people with multiple myeloma that has returned or stopped responding to standard treatments. It aims to see if targeting a specific protein on myeloma cells can help control the disease.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This trial tests a new type of immune cell therapy (called CAR T-cells) designed to treat advanced multiple myeloma that has not responded well to standard treatments. The study focuses on safety and how well your body tolerates this personalized cell therapy.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.